differentiate from amelanotic melanoma. The primaries for iris metastasis include breast, lung, carcinoid, melanoma, colon, oesophagus, larynx, prostate, kidney, S uterus8 and cervix. 9 Various investigations are required to confirm the diagnosis. Fluorescein angiography of the anterior segment is a useful tool and shows the lesion as hypofluorescent in the early stages with late hyperfluorescence. Ultrasound biomicroscopy, lO whilst confirming the solid nature of the lesion and the extent of any posterior (ciliary body) extension, cannot differentiate between primary and secondary tumours. Fine needle aspiration biopsyll, 1 2 was therefore required to establish the diagnosis.
This case illustrates that though non-invasive tests may provide information about the lesion a fine needle aspiration biopsy still remains one of the definitive investigations for any iris lesion. 
Case report
A 76-year-old man had been attending eye casualty for 2 weeks with a viral disciform keratouveitis affecting his right eye. He was receiving topical steroid having previously received a course of topical aciclovir. Visual acuities were: right eye 6/60, left eye, counting fingers. During follow-up review he was noted to have 2+ cells and flare in the anterior chamber and 3600 posterior synechiae in the right eye. Dilatation was attempted using initially tropicamide 1%, then cyclopentolate 1% and finally atropine 1% drops. A period of 30 min was left between drops. Unfortunately mydriasis did not occur and a decision was made to give subconjunctival Mydricaine No. 2, 0.3 ml, to facilitate mydriasis and break the posterior synechiae.
The patient had no previous cardiac history and nothing to suggest contraindication to the Mydricaine injection. His pulse rate prior to injection was 80 beats/ min and regular. Two minutes after administration of the subconjunctival Mydricaine No. 2 the patient complained of palpitations; there was no shortness of breath or chest pain. Cardivascular examination revealed an irregular pulse, with a rate of 110 beats/ min. He was haemodynamically stable. An electrocardiogram (ECG) confirmed sinus rhythrp. and supraventricular ectopics at a rate of 100 beats/ min (Fig. 1) . Whilst undertaking the ECG the patient complained of breathlessness and was found at this stage to have a pulse rate of 200 beats / min, with the ECG showing a supraventricular tachycardia ( Fig. 2) . This resolved over a period of 5 min and the supraventricular ectopics resolved over a period of 1 h, confirmed by ECG (Fig. 3) . Electrolyte levels were found to be with the normal range. The patient was discharged later following physician review, to attend for a cardiology outpatient appointment. Due to the fact that Mydricaine No. 2 is produced under special licence it is not listed in the BNF or MIMS and there is no data sheet provided with this drug, which makes it difficult to find information regarding possible side effects resulting from its usage. Steel and Thorn 1 suggested that observations be performed during and following administration of Mydricaine, though the form and timing of these observations has not been specified. We suggest that administration guidelines for this commonly used formulation should be drawn up. Being an unlicensed product the responsibility following administration lies with the prescriber, 4 who unfortunately at present does not have access to possible complications that may result from its usage.
